+91-6280082254
Reviewed by Dr. Lovedeep Singh Chauhan, MS, MCh (Surgical Oncology) | Senior Surgical Oncologist Trained at Tata Memorial Hospital, Mumbai Practicing at Max Super Speciality Hospital, Mohali This article is written for patient education purposes only and does not constitute personal medical advice.
Introduction
You have just received your PET-CT report. It is several pages long, filled with medical terms you have never seen before words like "hypermetabolic lesion," "SUVmax," "FDG avid," and "mediastinal lymphadenopathy." Most patients fold the report, put it in a file, and wait anxiously for their doctor's appointment to make sense of it.
This guide is written to change that experience. Understanding even the basics of your PET-CT report will help you ask better questions, feel less afraid, and participate more confidently in your own treatment decisions. Patients consulting an oncologist in Punjab often arrive at their appointment visibly relieved when they have read something like this beforehand.
This is not a substitute for your oncologist's interpretation. Every report must be read in the context of your full clinical history. But knowledge is never wasted, and understanding your report is a reasonable and empowering thing to want.
What Is a PET-CT Scan?
A PET-CT scan combines two imaging technologies into one examination: a PET (Positron Emission Tomography) scan and a CT (Computed Tomography) scan performed simultaneously on the same machine.
The CT part creates detailed structural images of your organs, bones, and tissues essentially a high-resolution map of your body's anatomy. The PET part measures metabolic activity how actively different cells in your body are consuming glucose (sugar). Cancer cells consume far more glucose than normal cells, which is the core principle behind why PET scans detect cancer so effectively.
Before the scan, you are injected with a small amount of radioactive glucose called FDG (Fluorodeoxyglucose). Your body absorbs this glucose normally, but cancer cells absorb it far more intensely. The PET scanner detects where this activity is concentrated, and the CT scan shows exactly where in the body that activity is located. Together, they give your oncologist a precise picture of both the location and the metabolic behaviour of any suspicious areas.
Why Has Your Doctor Ordered a PET-CT?
PET-CT scans are ordered for several specific reasons in cancer care, and knowing why yours was requested gives context to how you read the report.
Initial staging - After a cancer diagnosis, a PET-CT helps determine whether the cancer is localised (confined to one area) or has spread to lymph nodes or distant organs. This directly determines your treatment plan whether surgery alone is enough, or whether chemotherapy or radiation is needed first or alongside.
Treatment response assessment - After chemotherapy, targeted therapy, or radiation, a PET-CT shows whether the cancer has responded. A reduction in FDG activity suggests the treatment is working.
Detecting recurrence - If cancer symptoms return after treatment, or if your tumour markers rise, a PET-CT can identify whether and where the cancer has come back before it becomes visible on a regular CT scan.
Surgical planning - For surgical oncologists like Dr. Lovedeep Singh Chauhan , PET-CT reports are critical in planning operations for colorectal cancers , gynaecological malignancies , head and neck cancers , and other complex resections, helping determine which structures need to be removed and what can be safely preserved.
Reading Your PET-CT Report: Section by Section
A standard PET-CT report has several sections. Here is what each one means in plain language.
Clinical History and Indication
This section at the top of your report simply states why the scan was done for example, "known case of carcinoma rectum, post-chemotherapy, for response assessment." It confirms the scan was ordered for your specific situation. Read this to verify the report is indeed yours and the indication matches what your doctor told you.
Technique
This section describes how the scan was performed, the dose of FDG injected, how long after injection the scan was done, and the imaging parameters used. You do not need to analyse this section. It is primarily for the reporting radiologist and your oncologist to confirm the scan was technically adequate for interpretation.
Findings
This is the most important section of your report and the one patients most want to understand. The radiologist describes every area of abnormal FDG activity found in the body, along with CT measurements of any visible masses or lymph nodes.
The findings section typically moves systematically through the body head and neck, chest, abdomen, pelvis, and then bones. Each area of concern is described with its location, size, and metabolic activity level.
Key Terms in the Findings Section — Explained Simply
FDG Avid / FDG Uptake
"FDG avid" means an area is absorbing the radioactive glucose more than surrounding normal tissue. The degree of uptake is what matters. Mild FDG uptake can be seen in inflammation or infection, not only cancer. Intense or markedly increased FDG uptake in a mass is more concerning and is what your oncologist focuses on.
SUVmax (Standardised Uptake Value)
This is a number that measures how intensely a particular area is absorbing FDG. Think of it as a metabolic activity score. There is no universal "normal" or "cancer" cutoff for SUVmax interpretation depending on the organ, the type of cancer, and the clinical context. However, as a general orientation:
SUVmax below 2.5 is often considered low activity and may represent normal tissue or mild inflammation. SUVmax between 2.5 and 5 is borderline and requires clinical correlation. SUVmax above 5 particularly in a known or suspected tumour is considered significantly elevated and is treated as suspicious for active malignancy by most oncologists.
Do not fixate on the exact number in isolation. Your oncologist interprets it alongside everything else they know about you.
Hypermetabolic Lesion
This phrase means an area showing abnormally high metabolic activity on PET imaging. "Hypermetabolic lesion in the left lobe of the liver" means there is a spot in the liver that is consuming glucose at a higher-than-normal rate. This is the phrase that understandably causes the most anxiety but it does not automatically confirm cancer spread. Your oncologist determines whether it is truly malignant based on your full clinical picture.
Hypometabolic / Photopenic Area
The opposite of hypermetabolic. This means reduced or absent FDG uptake sometimes seen in areas of dead tissue (necrosis), cysts, or benign lesions. In a previously treated tumour, a hypometabolic area may indicate treatment response good news.
Lymphadenopathy
This means enlarged lymph nodes. When the report says "FDG avid lymphadenopathy in the para-aortic region," it means enlarged lymph nodes near the aorta that are showing metabolic activity. Whether these nodes contain cancer depends on their size, SUVmax, and clinical context. Lymph nodes can also enlarge due to infection or inflammation.
Lytic / Sclerotic Lesion
These terms describe findings on the CT component of the scan. A lytic lesion in bone means an area where bone has been destroyed can be caused by cancer spread (metastasis) or other conditions. A sclerotic lesion means denser-than-normal bone, sometimes a sign of healing or certain types of metastasis. Both need clinical correlation before conclusions are drawn.
The Impression / Conclusion Section
At the end of every PET-CT report is a summary section usually titled "Impression" or "Opinion." This is where the radiologist consolidates all findings into a brief, structured conclusion. For example:
"Metabolically active primary lesion in the sigmoid colon with FDG avid regional mesenteric lymph nodes. No evidence of distant metastatic disease."
This section is what your oncologist reads first. It tells the overall story of the scan in 2–5 lines. When you read your report, go to this section to get the headline, and then read the findings section to understand the details behind it.
What Does "No Evidence of Metastatic Disease" Mean?
This is one of the most reassuring phrases in a PET-CT report. It means the scan has not detected FDG avid lesions in distant organs — no visible or metabolically active spread to the liver, lungs, bones, or other distant sites at the time of scanning.
It does not mean cancer is 100% absent everywhere PET-CT has limits in detecting very small microscopic deposits below a certain size. But for practical surgical and treatment planning purposes, "no evidence of metastatic disease" is highly significant and often means the cancer is potentially curable with surgery.
What Does "Complete Metabolic Response" Mean?
If you had a PET-CT after completing chemotherapy or radiation, you may see this phrase in the conclusion. Complete metabolic response means there is no longer any abnormal FDG uptake detected in the areas that were previously active. In simple terms the cancer is no longer showing metabolic activity on the scan.
This is considered an excellent outcome. For some cancers particularly rectal cancer and lymphomas — a complete metabolic response after treatment may mean surgery can be planned with very favourable intent, or in select cases, surveillance rather than immediate surgery may be considered. Your oncologist and surgical team will guide you on what this means for your specific situation.
Common Mistakes Patients Make When Reading PET-CT Reports
Many patients read their report before seeing their doctor, which is understandable. However, certain patterns of misinterpretation cause unnecessary distress.
Focusing only on the SUVmax number without knowing the clinical context leads to misplaced panic or false reassurance. Assuming every "FDG avid" area means cancer spread, in fact, the brain, heart, kidneys, and bladder all show normal FDG activity and appear prominently in every report. Comparing your current report to a previous one without knowing what changed in between — a rise in SUVmax does not always mean worsening cancer; it can reflect infection or technical variation. Reading only the findings and missing the impression is the radiologist's final, considered conclusion and carries more weight than individual sentences in the findings.
Bring your PET-CT report to your consultation with Dr. Lovedeep Singh Chauhan along with all previous scans and reports. Comparing scans over time, known as serial imaging, is often more informative than any single report in isolation.
PET-CT and Surgical Planning
For a surgical oncologist, the PET-CT report is one of the most important documents in the pre-operative workup. It helps determine whether a cancer is resectable meaning surgically removable — or whether chemotherapy or radiation should be given first to shrink the tumour before surgery.
In colorectal cancer surgery, the PET-CT helps identify involved lymph nodes and rule out liver metastases before planning a major resection. In gynaecological malignancies such as ovarian or cervical cancer, it guides the extent of surgery needed and whether adjacent structures are involved. In head and neck cancers, the PET-CT maps nodal disease with precision that guides both the surgical and radiation fields. In endocrine malignancies like thyroid cancer, it helps identify distant spread that would change the surgical approach significantly.
Understanding your PET-CT report even partially means you can have a far more meaningful conversation with your surgeon about what the findings mean for your specific operation.
Frequently Asked Questions (FAQs)
Dr. Lovedeep Singh Chauhan
Dr. Lovedeep Singh Chauhan is a Consultant in Surgical Oncology at Max Super Speciality Hospital, Mohali (2023–present). He has received advanced training in cancer surgery from leading national institutes and has academic, clinical, and research experience across multiple subspecialties of surgical oncology.
>
